Breaking News Instant updates and real-time market news.

AMGN

Amgen

$174.63

0.9 (0.52%)

19:06
05/17/18
05/17
19:06
05/17/18
19:06

Amgen receives FDA approval for Aimovig in migraine treatment

Amgen announced that the U.S. Food and Drug Administration has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor - which is believed to play a critical role in migraine. Aimovig 70 mg is self-administered once monthly via Amgen's device, the SureClick autoinjector, and does not require a loading dose. Some patients may benefit from a dosage of 140 mg once monthly. In Phase 2 and 3 studies in chronic and episodic migraine, Aimovig resulted in significant reductions in monthly migraine days and use of acute migraine medications compared to placebo. These effects on monthly migraine days have been shown to be sustained for up to 15 months in an ongoing open-label extension study in episodic migraine (four to 14 headache days per month). A dedicated Phase 3b study in difficult-to-treat populations - those with episodic migraine who have failed two to four prior treatments - showed that patients taking Aimovig had nearly three-fold higher odds of having their migraine days cut by half or more compared to placebo. The efficacy, tolerability and safety of Aimovig has been assessed in more than 3,000 patients, including LIBERTY and an ongoing open-label extension of up to five years in duration. In clinical studies of Aimovig, the most common adverse reactions were injection site reactions and constipation.

  • 17

    May

  • 22

    May

  • 28

    May

AMGN Amgen
$174.63

0.9 (0.52%)

04/25/18
RBCM
04/25/18
NO CHANGE
Target $183
RBCM
Sector Perform
Amgen price target lowered to $183 from $189 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $183 and kept his Sector Perform rating after the company's Q1 results. The analyst notes that despite the earnings beat and higher FY18 midpoint guidance, he is more cautious as Amgen's base products drove the revenue gains. MacKay adds that he remains concerned by the competitive threats to Amgen's legacy business.
04/25/18
COWN
04/25/18
NO CHANGE
Target $204
COWN
Outperform
Amgen shares remain undervalued, says Cowen
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
05/15/18
MZHO
05/15/18
NO CHANGE
Target $200
MZHO
Buy
Amgen buyback activity could buoy shares, says Mizuho
Mizuho analyst Salim Syed says that for Amgen to buy back the $2B-$4B of its own stock this quarter, as it said it would do, it would have to make up 5%-11% of daily volume traded every day in the current quarter. The analyst is "not fully convinced this math has been entirely digested by the Street." This could potentially act as a buoy for the stock this quarter, Syed tells investors in a research note. The analyst keeps a Buy rating on the shares with a $200 price target.
05/16/18
MSCO
05/16/18
NO CHANGE
Target $200
MSCO
Overweight
Epogen biosimilar should have little impact on Amgen, says Morgan Stanley
After the FDA approved Retacrit, Pfizer's (PFE) biosimilar version of Amgen's (AMGN) Epogen, Morgan Stanley analyst Matthew Harrison said he does not see significant impact to his forecasts due to the news, noting that Amgen has already discounted Epogen net selling price significantly to secure an extended supply agreement with DaVita (DVA). Amgen renegotiated the supply agreement in early 2017 and the vast majority of Epogen volume is from DaVita, added Harrison, who maintains an Overweight rating and $200 price target on Amgen shares.

TODAY'S FREE FLY STORIES

TLRY

Tilray

$154.99

34.79 (28.94%)

08:55
09/19/18
09/19
08:55
09/19/18
08:55
Hot Stocks
Tilray shares go mad after CEO appears on CNBC's Mad Money »

Shares of Tilray (TLRY),…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$31.93

-0.51 (-1.57%)

, FTV

Fortive

$87.39

0.25 (0.29%)

08:55
09/19/18
09/19
08:55
09/19/18
08:55
Options
Notable open interest changes for September 19th »

Tuesday's total…

AMD

AMD

$31.93

-0.51 (-1.57%)

FTV

Fortive

$87.39

0.25 (0.29%)

BAC

Bank of America

$30.22

-0.05 (-0.17%)

PBR

Petrobras

$11.23

0.305 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 27

    Sep

AZO

AutoZone

$732.74

-14.79 (-1.98%)

, AAP

Advance Auto Parts

$167.64

4.25 (2.60%)

08:54
09/19/18
09/19
08:54
09/19/18
08:54
Recommendations
AutoZone, Advance Auto Parts, O'Reilly Automotive analyst commentary  »

AutoZone price target…

AZO

AutoZone

$732.74

-14.79 (-1.98%)

AAP

Advance Auto Parts

$167.64

4.25 (2.60%)

ORLY

O'Reilly Automotive

$340.65

3.98 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TLRY

Tilray

$154.99

34.79 (28.94%)

08:53
09/19/18
09/19
08:53
09/19/18
08:53
Hot Stocks
Citron says still short Tilray, recent rally 'beyond comprehension' »

Short-seller Citron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROW

T. Rowe Price

$109.29

0.3 (0.28%)

08:53
09/19/18
09/19
08:53
09/19/18
08:53
Conference/Events
T. Rowe Price management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

08:53
09/19/18
09/19
08:53
09/19/18
08:53
Conference/Events
Roth Capital to hold a conference »

4th Annual Datacenter…

08:50
09/19/18
09/19
08:50
09/19/18
08:50
Conference/Events
Canaccord to hold a conference »

Artificial Intelligence…

08:50
09/19/18
09/19
08:50
09/19/18
08:50
General news
U.S. Q2 current account deficit narrowed to -$101.5 B »

U.S. Q2 current account…

08:50
09/19/18
09/19
08:50
09/19/18
08:50
General news
Treasury Action: yields drifted below highs »

Treasury Action: yields…

HEAR

Turtle Beach

$17.75

-1.55 (-8.03%)

08:49
09/19/18
09/19
08:49
09/19/18
08:49
Recommendations
Turtle Beach analyst commentary  »

Turtle Beach 45% pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEA

Lear

$154.96

-2.2 (-1.40%)

08:47
09/19/18
09/19
08:47
09/19/18
08:47
Recommendations
Lear analyst commentary  »

Lear price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TNDM

TNDM

08:47
09/19/18
09/19
08:47
09/19/18
08:47
Conference/Events
Tandem Diabetes management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 25

    Sep

  • 27

    Nov

GWPH

GW Pharmaceuticals

$149.14

8.165 (5.79%)

08:47
09/19/18
09/19
08:47
09/19/18
08:47
Recommendations
GW Pharmaceuticals analyst commentary  »

Launch of GW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

TFX

Teleflex

$269.03

1.81 (0.68%)

08:46
09/19/18
09/19
08:46
09/19/18
08:46
Conference/Events
Teleflex management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

  • 09

    Oct

NVS

Novartis

$85.03

-0.1 (-0.12%)

08:46
09/19/18
09/19
08:46
09/19/18
08:46
Conference/Events
Novartis has a conference call hosted by JPMorgan »

JPMorgan Analyst Vosser …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

SPWH

Sportsman's Warehouse

$6.15

-0.02 (-0.32%)

08:45
09/19/18
09/19
08:45
09/19/18
08:45
Conference/Events
Sportsman's Warehouse management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

08:45
09/19/18
09/19
08:45
09/19/18
08:45
General news
U.S. housing starts rose 9.2% to 1.282 M in August »

U.S. housing starts rose…

SSC

Seven Stars Cloud Group

$4.38

-0.3 (-6.41%)

, CBL

CBL & Associates

$4.34

0.005 (0.12%)

08:45
09/19/18
09/19
08:45
09/19/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

SSC

Seven Stars Cloud Group

$4.38

-0.3 (-6.41%)

CBL

CBL & Associates

$4.34

0.005 (0.12%)

MELI

MercadoLibre

$315.06

-7.02 (-2.18%)

SQQQ

ProShares UltraPro Short QQQ

$11.80

-0.3 (-2.48%)

GERN

Geron

$5.48

0.05 (0.92%)

KEY

KeyCorp

$19.74

-0.11 (-0.55%)

CGC

Canopy Growth

$51.77

3.25 (6.70%)

SGYP

Synergy Pharmaceuticals

$1.69

0.005 (0.30%)

SDS

UltraShort S&P500 ProShares

$33.45

-0.41 (-1.21%)

AMJ

American Medical Laboratories Inc

$27.87

0.04 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

  • 13

    Oct

  • 18

    Oct

  • 30

    Oct

  • 30

    Oct

08:45
09/19/18
09/19
08:45
09/19/18
08:45
General news
FX Action: The dollar »

FX Action: The dollar was…

08:45
09/19/18
09/19
08:45
09/19/18
08:45
General news
U.S. Q2 current account deficit narrowed to -$101.5 B »

U.S. Q2 current account…

ATHN

Athenahealth

$135.25

-8.005 (-5.59%)

08:43
09/19/18
09/19
08:43
09/19/18
08:43
Recommendations
Athenahealth analyst commentary  »

Leerink sees risk of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEIC

SEI Investments

$62.66

0.26 (0.42%)

08:42
09/19/18
09/19
08:42
09/19/18
08:42
Conference/Events
SEI Investments management to meet with Oppeheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

08:40
09/19/18
09/19
08:40
09/19/18
08:40
Conference/Events
The Atlanta Society of Finance & Investment Professionals to hold a meeting »

The Atlanta Society of…

OCFC

OceanFirst Financial

$28.39

-0.16 (-0.56%)

, SBBX

SB One Bancorp

$26.10

-0.5 (-1.88%)

08:39
09/19/18
09/19
08:39
09/19/18
08:39
Conference/Events
DA Davidson to hold a conference »

The Mid-Atlantic…

OCFC

OceanFirst Financial

$28.39

-0.16 (-0.56%)

SBBX

SB One Bancorp

$26.10

-0.5 (-1.88%)

WSFS

WSFS Financial

$47.93

-0.475 (-0.98%)

MBCN

Middlefield Banc

$47.35

-1.15 (-2.37%)

FFDF

FFD Financial

$0.00

(0.00%)

WSBC

WesBanco

$45.70

-0.74 (-1.59%)

EMCF

Emclaire Financial

$37.00

-0.45 (-1.20%)

TSC

TriState Capital

$28.40

-0.25 (-0.87%)

STBA

S&T Bancorp

$45.27

(0.00%)

SMMF

Summit Financial Group

$24.75

0.39 (1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 24

    Sep

  • 23

    Oct

CSII

Cardiovascular Systems

$38.05

0.47 (1.25%)

08:39
09/19/18
09/19
08:39
09/19/18
08:39
Recommendations
Cardiovascular Systems analyst commentary  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.